RGEN Stock Price Chart More Charts

RGEN Price/Volume Stats

Repligen Corporation (RGEN) Company Bio

Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.

RGEN Price Forecast Based on DCF Valuation

We started the process of determining a valid price forecast for Repligen Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Repligen Corp ranked in the 10st percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Repligen Corp ended up being:

• 95% of the company's capital comes from equity, which is greater than 84.03% of stocks in our cash flow based forecasting set.
• The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 15.93% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
• As a business, Repligen Corp experienced a tax rate of about 12% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 54.85% of stocks generating free cash flow.

Want more companies with a valuation profile/forecast similar to that of Repligen Corp? See MEDS, PRSC, LCTC, SRDX, and BSX.